← Leaderboards
Edward P Gelmann
Georgetown University
$8,316,737
Attributed
$8,316,737
Total exposure
12
Grants
7
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $673.8K · FY2005–25$1M$750K$500K$250K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$8,316,737 · 12
By mechanism
R01$2,795,712 · 3
P30$2,373,658 · 3
P01$971,371 · 1
U10$893,657 · 1
N01$816,839 · 2
R21$312,000 · 1
Top collaborators
No co-investigators on record.
Most similar at Georgetown University
Same institution · by research overlap
- Jeanne Mandelblatt$29,742,067
Others in their field
Top investigators on “Clinical Research”
- David Heimbrook · Leidos Biomedical Research, Inc.$1,040,569,537
- Leonard Freedman · Leidos Biomedical Research, Inc.$975,089,882
- Lawrence Corey · Fred Hutchinson Cancer Center$739,766,552
- Sonia M Thomas · Research Triangle Institute$700,865,642
- Jeffrey P Krischer · University Of South Florida$611,867,176
- Barton F Haynes · Duke University$538,862,577
Research focus
Clinical ResearchClinical TrialsProstate NeoplasmsCancer Center Support GrantPeer ReviewProtocols DocumentationGrantOffice ManagementReportingBudgetsHerbert Irving Comprehensive Cancer CenterFundingData ManagementNursing ResearchResearch PersonnelServicesUniversitiesProgramsAndrogen ReceptorCancer TherapyMalignant NeoplasmsMonitorCancer CenterHuman Subject
Grant awards (47)
Protocol Review and Monitoring System (PRMS)$85,531
P30 · FY2025 · CA · contact PI
Protocol Review and Monitoring System (PRMS)$79,372
P30 · FY2024 · CA · contact PI
DYRK1B Inhibition for Prostate Cancer$153,500
R03 · FY2023 · TR · contact PI
Protocol Review and Monitoring System (PRMS)$79,372
P30 · FY2023 · CA · contact PI
Role of the DNA Damage Response in Prostate Cancer Initiation$247,222
P01 · FY2015 · CA · contact PI
Role of the DNA Damage Response in Prostate Cancer Initiation$240,331
P01 · FY2014 · CA · contact PI
Role of the DNA Damage Response in Prostate Cancer Initiation$233,405
P01 · FY2013 · CA · contact PI
CRMO- CLINICAL RESEARCH MANAGEMENT OFFICE$136,392
P30 · FY2013 · CA · contact PI
PROTOCOL SPECIFIC RESEARCH RESOURCE$136,392
P30 · FY2013 · CA · contact PI
CRMO- CLINICAL RESEARCH MANAGEMENT OFFICE$327,946
P30 · FY2012 · CA · contact PI
Role of the DNA Damage Response in Prostate Cancer Initiation$250,413
P01 · FY2012 · CA · contact PI
PROTOCOL SPECIFIC RESEARCH RESOURCE$95,395
P30 · FY2012 · CA · contact PI
CRMO- CLINICAL RESEARCH MANAGEMENT OFFICE$284,055
P30 · FY2011 · CA · contact PI
PROTOCOL SPECIFIC RESEARCH RESOURCE$106,522
P30 · FY2011 · CA · contact PI
CRMO- CLINICAL RESEARCH MANAGEMENT OFFICE$290,105
P30 · FY2010 · CA · contact PI
PROTOCOL SPECIFIC RESEARCH RESOURCE$108,791
P30 · FY2010 · CA · contact PI
CRMO- CLINICAL RESEARCH MANAGEMENT OFFICE$288,870
P30 · FY2009 · CA · contact PI
PROTOCOL SPECIFIC RESEARCH RESOURCE$108,326
P30 · FY2009 · CA · contact PI
CRMO- CLINICAL RESEARCH MANAGEMENT OFFICE$3,524
P30 · FY2009 · CA · contact PI
PROTOCOL SPECIFIC RESEARCH RESOURCE$1,322
P30 · FY2009 · CA · contact PI
CRMO- CLINICAL RESEARCH MANAGEMENT OFFICE$175,813
P30 · FY2008 · CA · contact PI
PROTOCOL SPECIFIC RESEARCH RESOURCE$65,930
P30 · FY2008 · CA · contact PI
Genetic Polymorphism in Prostate Cancer$217,537
R01 · FY2007 · ES · contact PI
Genetic Polymorphism in Prostate Cancer$165,935
R01 · FY2006 · ES · contact PI
Cancer and Leukemia Group B$163,542
U10 · FY2006 · CA · contact PI
Genetic Polymorphism in Prostate Cancer$221,160
R01 · FY2005 · ES
Beta Catenin in Prostate Cancer$221,160
R01 · FY2005 · CA
Cancer and Leukemia Group B$163,331
U10 · FY2005 · CA
Beta Catenin in Prostate Cancer$221,160
R01 · FY2004 · CA
Genetic Polymorphism in Prostate Cancer$221,160
R01 · FY2004 · ES
Cancer and Leukemia Group B$168,198
U10 · FY2004 · CA
Beta Catenin in Prostate Cancer$288,587
R01 · FY2003 · CA
Genetic Polymorphism in Prostate Cancer$221,160
R01 · FY2003 · ES
Cancer and Leukemia Group B$140,262
U10 · FY2003 · CA
PROSTATE, LUNG, COLORECTAL &OVARIAN CANCER SCREENING TRIA-261925522$0
N01 · FY2003 · CA
Beta Catenin in Prostate Cancer$221,160
R01 · FY2002 · CA
CANCER AND ACUTE LEUKEMIA GROUP B (CALGB) INST GRANT$116,535
U10 · FY2002 · CA
GENETIC POLYMORPHISM IN PROSTATE CANCER$208,854
R01 · FY2001 · ES
APOPTOSIS IN PROSTATE CANCER$193,218
R01 · FY2001 · CA
BETA CATENIN IN PROSTATE CANCER$156,000
R21 · FY2001 · CA
CANCER AND ACUTE LEUKEMIA GROUP B (CALGB) INST GRANT$141,789
U10 · FY2001 · CA
PROSTATE, LUNG, COLORECTAL &OVARIAN CANCER$447,194
N01 · FY2000 · CN
PROSTATE, LUNG, COLORECTAL &OVARIAN CANCER$290,150
N01 · FY2000 · CN
GENETIC POLYMORPHISM IN PROSTATE CANCER$205,530
R01 · FY2000 · ES
APOPTOSIS IN PROSTATE CANCER$189,091
R01 · FY2000 · CA
BETA CATENIN IN PROSTATE CANCER$156,000
R21 · FY2000 · CA
PROSTATE, LUNG, COLORECTAL &OVARIAN CANCER$79,495
N01 · FY2000 · CN